← CNS Pharmaceuticals, Inc. (CNSP) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
CNS Pharmaceuticals, Inc. (CNSP)
Pharmaceutical Preparations · market cap $8M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-13 (est.)
Earnings
Pipeline
1
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
CNS Pharmaceuticals (CNSP) is a micro-cap clinical-stage biotech with 4 employees and an ~$8M market cap, focused entirely on Berubicin, an anthracycline derivative in Phase 2 for recurrent or newly diagnosed Glioblastoma Multiforme (GBM) in adults. The company holds approximately $3.0M in cash against a reported runway of under two months, creating acute near-term financing risk. No upcoming catalysts are calendared and no recent data readouts have been disclosed.
The catalyst path
- 2026-11-13 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Berubicin | Phase 2 | Glioblastoma Multiforme, Adult |
Price & technical context
3-month
+7.8%
6-month
+137.6%
12-month
-38.3%
52-wk range
$2.13–$10.57
vs 50-day MA
-1.7%
vs 200-day MA
+14.6%
Realized vol
146.8%
Max drawdown
-97.8%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CNSP (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 1 registered trial on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.